about
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortiumRecommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.The lack of laminin-5 as a prognostic marker in low-grade cervical squamous intraepithelial lesions: correlation with clinical follow-up data.Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.A prognostic gene expression index in ovarian cancer - validation across different independent data sets.KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).Association of myeloperoxidase with ovarian cancer.Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patientsPrognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD ConsortiumFive genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues.Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.Biochip-based detection of KRAS mutation in non-small cell lung cancer.AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcomeClinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumIn ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors.Rapid quantitative analysis of differential PCR products by high-performance liquid chromatography.Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasiaSmall cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring.Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortiumSensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.New and potential clinical applications of KRAS as a cancer biomarker.
P50
Q28275893-BF0CC357-BB3F-40B7-A2B3-3899609E9286Q30235460-F6D3AC5B-8863-4698-ACA0-C9D3689941B7Q30656720-16EEF9F5-81CA-4D0E-BFD8-AEFE5D3C07ACQ31089181-0426D249-FE4F-4C84-B1EB-FC25BFC64D00Q33193778-1C783B5B-FB47-4A86-9158-05C388551A6CQ33415702-F6AF937C-4530-4913-B8F5-EC09F26FE961Q33419209-D79FDEF4-C4F7-4ECB-B434-877498A6FD86Q33428782-8A9B438A-9C6C-4C41-8ADE-F2CD9CD2917BQ33438805-28750FCA-8FCB-4AB9-AB13-81C48D9EF2D2Q33456583-BD2F519B-864D-466D-A278-8BDB70B6D74CQ33689246-45DF557E-E51B-443C-B1CA-7230D77C329BQ33750749-F03592CE-4781-4EBE-9783-DAEEFFE7C733Q33762644-3DD1579B-F459-4694-B0E2-E274E745A2CAQ33772182-83C5F6A6-E631-4FB3-A3CD-0C7DF56BB403Q34135353-B9DF991C-588C-4EB6-B780-FABD11AE2FD3Q34198666-A292E144-18E8-44B8-B98D-3D67862E90EFQ34465346-97818A42-6081-449D-B106-A44E41A4E9BEQ34646749-C98522DC-95F6-4160-8C22-40D41E029CA1Q35015274-2D48C263-257E-4414-A198-A7A1ED9DE167Q35623109-EB48E779-357F-448B-9E4C-F33E91F9D1B4Q35669440-90C1DA68-D73E-46CD-B306-BCB81FAF6CF0Q36104522-8ACB34F7-0EAD-4015-975A-69D54E48294DQ36136448-9C8323EC-06B3-4308-9B76-CD46AAD0FE5DQ36232027-D9625304-F8B0-4FA2-AA7B-C781B0431A89Q36328579-239A115F-5FE5-4C72-9925-6994AEDD2417Q36369334-15E06118-A3F7-4D03-9832-1935EFAAF7B0Q36498614-76FA53B6-8D3D-4D4A-817A-7A9A14182AD4Q36609813-E47D6950-CCBE-4E69-9931-9F4BB30B966DQ36651350-81164375-05AF-4312-8046-4B87DCD05200Q36741789-E679FFA2-CF08-4CDC-9206-211ECCFBC294Q37000854-07424AEC-993C-4A59-B18F-C0E3575DCDA4Q37176607-B83D494D-1CDC-4CE0-AE14-7B95DA40390EQ37179512-CE21F47F-2A41-4C4F-855D-E015CF7B4662Q37307888-3AAFA4FA-329D-4D11-ABBC-943952FD45F7Q37359509-1BA7C589-48A0-453D-B9EE-5B1C03A37450Q37396240-28952420-1794-4A1A-8D8D-69597CCDC8FCQ37660308-DF8FE25A-3841-4B64-910D-FCBB49234AF4Q37720579-77A7BDD0-E015-4911-9ED6-19DCE6D4DAA1Q37943205-EDAB6707-DE06-4F49-9452-8CB2C1372014Q38089885-C065288E-ACFD-4989-AE9E-1CDE736FDFB1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Robert Zeillinger
@ast
Robert Zeillinger
@en
Robert Zeillinger
@es
Robert Zeillinger
@nl
Robert Zeillinger
@sl
type
label
Robert Zeillinger
@ast
Robert Zeillinger
@en
Robert Zeillinger
@es
Robert Zeillinger
@nl
Robert Zeillinger
@sl
prefLabel
Robert Zeillinger
@ast
Robert Zeillinger
@en
Robert Zeillinger
@es
Robert Zeillinger
@nl
Robert Zeillinger
@sl
P106
P21
P31
P496
0000-0001-6771-4591